Alcobra Ltd. (NASDAQ:ADHD)’s share price was up 5.9% during mid-day trading on Monday . The stock traded as high as $4.32 and last traded at $4.30, with a volume of 61,932 shares changing hands. The stock had previously closed at $4.06.

Several equities research analysts recently weighed in on the company. Roth Capital reissued a “buy” rating and set a $12.00 price objective on shares of Alcobra in a report on Tuesday, June 21st. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Zacks Investment Research raised Alcobra from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.63.

The company has a 50-day moving average of $4.67 and a 200 day moving average of $4.65. The company’s market cap is $115.48 million.

Alcobra (NASDAQ:ADHD) last posted its earnings results on Monday, May 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, analysts anticipate that Alcobra Ltd. will post ($0.98) earnings per share for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.